Modulation of oligonucleotide CpGmediated immune stimulation by positional modification of nucleosides

Details for Australian Patent Application No. 2005218065 (hide)

Owner Idera Pharmaceuticals, Inc.

Inventors Agrawal, Sudhir

Agent Davies Collison Cave

Pub. Number AU-B-2005218065

Parent 67720

Filing date 3 October 2005

Wipo publication date 27 October 2005

Acceptance publication date 25 October 2007

International Classifications

C12N 15/11 (2006.01) Mutation or genetic engineering - DNA or RNA fragments

A61K 31/7125 (2006.01) - Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters

A61P 37/04 (2006.01) Drugs for immunological or allergic disorders

C07H 21/00 (2006.01) Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Event Publications

20 October 2005 Complete Application Filed

27 October 2005 Application Open to Public Inspection

  Published as AU-B-2005218065

25 October 2007 Application Accepted

  Published as AU-B-2005218065

1 November 2007 Assignment before Grant

  Hybridon, Inc. The application has been assigned to Idera Pharmaceuticals, Inc.

21 February 2008 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005218066-Apparatus and Method for Accurately Delimited Cryoablation

2005218064-System for evaluating skills of tobe-examined person